Use of a gonadotropin-releasing hormone agonist analogue for treatment of cyclic auditory dysfunction.
A patient with cyclic luteal phase high-frequency hearing loss is described. This was documented by pre- and post-menstrual audiograms indicating a 40-dB hearing loss in the luteal phase. This had been long-standing and was resistant to oral contraceptive therapy. A gonadotropin-releasing hormone agonist (nafarelin) was used to inhibit ovarian function and was successful in preventing loss of hearing for the 6-month treatment period.
Andreyko
J L
JL
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco.
Jaffe
R B
RB
D000328:Adult; D001299:Audiometry; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D034381:Hearing Loss / Q000188:drug therapy*; D006316:Hearing Loss, High-Frequency / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008183:Luteal Phase; D017274:Nafarelin
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone